Advertisement
Canada markets close in 1 hour 51 minutes

  • S&P/TSX

    21,987.29
    +101.91 (+0.47%)
     

  • S&P 500

    5,109.54
    +61.12 (+1.21%)
     

  • DOW

    38,326.29
    +240.49 (+0.63%)
     

  • CAD/USD

    0.7318
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    83.81
    +0.24 (+0.29%)
     

  • Bitcoin CAD

    87,491.42
    -814.23 (-0.92%)
     

  • CMC Crypto 200

    1,332.70
    -63.83 (-4.57%)
     

  • GOLD FUTURES

    2,350.30
    +7.80 (+0.33%)
     

  • RUSSELL 2000

    2,004.59
    +23.47 (+1.18%)
     

  • 10-Yr Bond

    4.6750
    -0.0310 (-0.66%)
     

  • NASDAQ

    15,945.23
    +333.47 (+2.14%)
     

  • VOLATILITY

    15.08
    -0.29 (-1.89%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6839
    +0.0018 (+0.26%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

Company News for Dec 10, 2019

Zacks Equity Research

  • Shares of ArQule, Inc. ARQL jumped 103.9% after Merck & Co., Inc. said it would buy the company in a deal worth $2.7 billion

  •  Shares of Synthorx, Inc. THOR soared 170.5% after Sanofi SA said that it will acquire the company for an aggregated equity value of around $2.5 billion

  • Shares of Canopy Growth Corporation CGC rose 14.2% after the company announced David Klein as the new CEO

  • Shares of Fate Therapeutics, Inc. FATE rose 41.3% after the company announced positive preliminary data from its FT596 study


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Synthorx, Inc. (THOR) : Free Stock Analysis Report
 
Fate Therapeutics, Inc. (FATE) : Free Stock Analysis Report
 
ArQule, Inc. (ARQL) : Free Stock Analysis Report
 
Canopy Growth Corporation (CGC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research